Search the Studies

155 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001696-CSurveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)Recruitment has not started3-120 YearsNCI Benign Neoplasm
001560-DCNIDCD Otolaryngology Clinical Protocol Biospecimen BankParticipants currently recruited/enrolled3-99 YearsNIDCDLaryngeal Neoplasm
18-DC-0051Biospecimen Procurement for the Study of Head and Neck DisordersParticipants currently recruited/enrolled3-120 YearsNCI Laryngeal Neoplasm
11-C-0190Collection of Tissue Blocks or Slides from Patients with CancerParticipants currently recruited/enrolled18-125 YearsNCI Benign Neoplasm
09-C-0242Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsParticipants currently recruited/enrolled4-125 YearsNCI Benign Neoplasm
00-CH-0160Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical TissueCompleted Study; data analyses ongoing3-70 YearsNICHDBenign Neoplasm
001961-CA Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774Participants currently recruited/enrolled18-120 YearsNCI Neoplasm
001784-CPhase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell TransplantationRecruitment has not started18-120 YearsNCI Neoplasm
001778-CA Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical CancerRecruitment has not started18-120 YearsNCI Neoplasm
001776-CA Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants with Locally Advanced or Metastatic Solid Tumor MalignanciesParticipants currently recruited/enrolled18-120 YearsNCI Neoplasm
001732-CA Phase 1 Study of the Polymerase Theta (POL-Theta) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid TumorsParticipants currently recruited/enrolled18-120 YearsNCI Neoplasm
001715-CA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-AssociRecruitment has not started12-120 YearsNCI Neoplasm
001695-CA Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid TumorsRecruitment has not started18-120 YearsNCI Neoplasm
001657-CPhase 1 Umbrella Trial of Erlotinib In Combination with Select Tyrosine Kinase Inhibitors In Adult Patients with Advanced Solid TumorsRecruitment has not started18-120 YearsNCI Neoplasm
001636-CCA Pilot Study of a Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) RecipientsRecruitment has not started18-100 YearsCC Neoplasm
001583-CA Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Completed Study; data analyses ongoing18-120 YearsNCI Neoplasm
001572-CA Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)Participants currently recruited/enrolled18-120 YearsNCI Neoplasm
001569-CA Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma PatientsRecruitment has not started18-100 YearsNCI Neoplasm
001567-CObservational Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided BiopsyParticipants currently recruited/enrolled35-120 YearsNCI Neoplasm
001554-CPhase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitment has not started12-120 YearsNCI Neoplasm
001547-CA First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and CarcinomasParticipants currently recruited/enrolled18-120 YearsNCI Neoplasm
001544-CPhase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with Entinostat and Nivolumab as Adjuvant Therapy following Chemoradiation Therapy with or without Surgery for Locally Advanced Esophageal CancerParticipants currently recruited/enrolled18-120 YearsNCI Neoplasm
001534-CPhase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN AmplificationsParticipants currently recruited/enrolled18-120 YearsNCI Benign
000954-CA Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing CancerNo longer recruiting/follow-up only18-120 YearsNCI Neoplasm
000732-CA Long-Term Follow-Up Study of Patients Who Received VOR33Participants currently recruited/enrolled18-125 YearsNCI Neoplasm
000697-HU01 Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)Participants currently recruited/enrolled18-65 YearsNHLBINeoplasm
000678-CRare Tumors and Cancer Predisposition in Individuals and FamiliesParticipants currently recruited/enrolled0-125 YearsNCI Neoplasm
000666-CA Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)Participants currently recruited/enrolled18-100 YearsNCI Neoplasm
000661-CComprehensive Molecular and Clinical Evaluation of Pediatric and Adult Myelodysplastic Syndromes (MDS)Participants currently recruited/enrolled0-120 YearsNCI Neoplasm
000611-CA Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
000580-CA Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2(alpha) Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell CarcinomParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
000491-CTissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)Participants currently recruited/enrolled18-125 YearsNCI Neoplasm
000489-CPhase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic MalignanciesParticipants currently recruited/enrolled12-120 YearsNCI Neoplasm
000473-CA Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic CholangiocarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
000464-HEvaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative TherapiesEnrolling by Invitation4-125 YearsNHLBINeoplasm
000359-CPhase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignanciesParticipants currently recruited/enrolled12-85 YearsNCI Neoplasm
000356-CA Phase I/II Trial of BMS-986253 in Myelodysplastic SyndromesNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
000307-CPhase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic CholangiocarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
000305-CExploratory Phase II Study of LAnreotide in Unresectable or Metastatic Pheochromocytoma / PARAgangliomaNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
000302-CA Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
000274-CPhase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
000237-CPhase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary CancerParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
000123-CCEvaluation of Atherosclerotic Plaques in Abdominal CT StudiesNo longer recruiting/follow-up only30-90 YearsCC Neoplasm
000103-CA Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
000067-CUnderstanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell TherapyCompleted Study; data analyses ongoing2-125 YearsNCI Neoplasm
000030-CPhase 2 Study of Bintrafusp alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).No longer recruiting/follow-up only18-125 YearsNCI Neoplasm
22-C-0005Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung CancerParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
21-I-0029Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)Participants currently recruited/enrolled3-125 YearsNIAIDBenign
21-C-0032GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor ExposureParticipants currently recruited/enrolled0-40 YearsNCI Neoplasm
21-C-0022A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR(TM) T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaParticipants currently recruited/enrolled10-75 YearsNCI Neoplasm
21-C-0006Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
21-C-0001A Phase I/II Study of M9241 with Docetaxel and Abiraterone in Adults with Metastatic Castration Sensitive and M9241 with Docetaxel in Castration Resistant Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
20-N-0019The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's DiseaseParticipants currently recruited/enrolled18-125 YearsNINDSBenign
20-C-0161Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic AnalysisParticipants currently recruited/enrolled6-125 YearsNCI Neoplasm
20-C-0150Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation CarriersParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
20-C-0130A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor PainNo longer recruiting/follow-up only12-120 YearsNCI Neoplasm
20-C-0121Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelParticipants currently recruited/enrolled18-120 YearsNCI Neoplasm
20-C-0069A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
20-C-0051Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology StudiesEnrolling by Invitation18-120 YearsNCI Neoplasm
20-C-0041Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic InjuriesEnrolling by Invitation1-125 YearsNCI Neoplasm
20-C-0028Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid LeukemiaParticipants currently recruited/enrolled3-35 YearsNCI Neoplasm
20-C-0024A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.Completed Study; data analyses ongoing18-120 YearsNCI Neoplasm
20-C-0023First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid TumorsParticipants currently recruited/enrolled12-120 YearsNCI Neoplasm
20-C-0022Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)Completed Study; data analyses ongoing18-125 YearsNCI Neoplasm
20-C-0012A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
19-C-0138Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)Participants currently recruited/enrolled18-125 YearsNCI Neoplasm
19-C-0128A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
19-C-0117A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing CancerNo longer recruiting/follow-up only18-120 YearsNCI Neoplasm
19-C-0112Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic MalignanciesParticipants currently recruited/enrolled12-120 YearsNCI Neoplasm
19-C-0040Natural History Study of Men at High Genetic Risk for Prostate CancerParticipants currently recruited/enrolled30-75 YearsNCI Neoplasm
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Neoplasm
18-N-0133Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal SurgeryParticipants currently recruited/enrolled18-85 YearsNINDSNeoplasm
18-CH-0031Clinical and Molecular Characteristics of Primary Aldosteronism in BlacksClinical hold/Recruitment or enrollment suspended7-70 YearsNIDDKNeoplasm
18-C-0093Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment TrialsCompleted Study; data analyses ongoing3-125 YearsNCI Benign
18-C-0078A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, N-803 and Epacadostat (QuEST1)No longer recruiting/follow-up only18-120 YearsNCI Neoplasm
18-C-0058A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy FemalesParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
18-C-0028A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy RadiotherapyNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
18-C-0014Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid TumorsParticipants currently recruited/enrolled18-120 YearsNCI Neoplasm
18-C-0008Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus ObservationNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
17-DC-0138Observational Study of Hearing Loss and the Effects of Statin Drugs in Head and Neck Squamous Cell Carcinoma Patients Treated with Cisplatin ChemoradiationCompleted Study; data analyses ongoing18-125 YearsNIDCDNeoplasm
17-C-0158A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer PatientsEnrolling by Invitation18-120 YearsNCI Neoplasm
17-C-0157A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)Completed Study; data analyses ongoing18-125 YearsNCI Neoplasm
17-C-0156Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer InstituteParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
17-C-0153Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior RadiotherapyNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
17-C-010918F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerEnrolling by Invitation18-125 YearsNCI Neoplasm
17-C-0092A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
17-C-0089Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate CancerEnrolling by Invitation18-125 YearsNCI Neoplasm
17-C-0087Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
17-C-0044Prospective Evaluation and Molecular Profiling in Patients with Gastric TumorsParticipants currently recruited/enrolled2-125 YearsNCI Neoplasm
17-C-0043Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric CancerParticipants currently recruited/enrolled2-125 YearsNCI Neoplasm
16-N-0041Tumor Related EpilepsyParticipants currently recruited/enrolled8-99 YearsNINDSNeoplasm
16-CC-0098Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate CancerClinical hold/Recruitment or enrollment suspended18-100 YearsCC Neoplasm
16-CC-0049A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal AblationCompleted Study; data analyses ongoing18-100 YearsCC Neoplasm
16-C-0171Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell LymphomaNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
16-C-0154A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated CancersParticipants currently recruited/enrolled18-120 YearsNCI Neoplasm
16-C-0151Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous SystemNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
16-C-0135A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)Completed Study; data analyses ongoing18-125 YearsNCI Neoplasm
16-C-0128A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
16-C-0121A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
16-C-0107A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate CancersParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
16-C-0097Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine GliomaCompleted Study; data analyses ongoing2-21 YearsNCI Neoplasm
16-C-0092A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)Completed Study; data analyses ongoing18-125 YearsNCI Neoplasm
16-C-0087Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
16-C-0066Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmCompleted Study; data analyses ongoing18-120 YearsNCI Neoplasm
16-C-0048Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate CancerNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
16-C-0034A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior BevacizumabCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
15-H-0172A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-125 YearsNHLBINeoplasm
15-C-0200Molecular Analysis for Therapy Choice (MATCH) (EAY131)Completed Study; data analyses ongoing18-125 YearsNCI Neoplasm
15-C-0160A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary TumorsNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
15-C-0150A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
15-C-0145Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
15-C-0116Phase I Trial of 4'-thio-2'-deoxycytidine (TdCyd) in Patients With Advanced Solid TumorsClinical hold/Recruitment or enrollment suspended18-125 YearsNCI Neoplasm
15-C-0086Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients with Refractory Solid TumorsParticipants currently recruited/enrolled12-120 YearsNCI Neoplasm
15-C-0076A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139Completed Study; data analyses ongoing18-125 YearsNCI Neoplasm
15-C-0075A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
14-C-0163Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic AnalysisCompleted Study; data analyses ongoing10-125 YearsNCI Benign
14-C-0161Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic SyndromesParticipants currently recruited/enrolled18-120 YearsNCI Neoplasm
14-C-0128Collection of Pharmacokinetic and Probe Substrate Samples from Participants with Unanticipated Response, Significant Toxicity or Concern of Future ToxicityEnrolling by Invitation2-125 YearsNCI Neoplasm
13-C-0202Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing CancersParticipants currently recruited/enrolled2-125 YearsNCI Neoplasm
13-C-0176Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid TumorsParticipants currently recruited/enrolled2-125 YearsNCI Neoplasm
13-C-0119Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided BiopsiesParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
13-C-0105Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsCompleted Study; data analyses ongoing18-120 YearsNCI Neoplasm
12-H-0064A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other IndicationsParticipants currently recruited/enrolled4-75 YearsNHLBINeoplasm
12-H-0035A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p DeletionNo longer recruiting/follow-up only18-125 YearsNHLBINeoplasm
12-C-0205A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
12-C-0118A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic ChemotherapyNo longer recruiting/follow-up only18-100 YearsNCI Neoplasm
12-C-0081Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast CancerNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
12-C-0079A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
12-C-0066Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
11-CC-0152The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV InfectionCompleted Study; data analyses ongoing18-99 YearsCC Neoplasm
11-C-0255Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni SyndromeParticipants currently recruited/enrolled0-125 YearsNCI Neoplasm
11-C-0247A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for untreated, intermediate and High Risk Prostate Cancer PatientsCompleted Study; data analyses ongoing18-100 YearsNCI Neoplasm
11-C-0140A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
11-C-0061Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI Neoplasm
10-CC-0217A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue BiopsyCompleted Study; data analyses ongoing18-125 YearsCC Neoplasm
10-C-0056A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
09-C-0139A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
09-C-0053Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow DonEnrolling by Invitation1-125 YearsNCI Neoplasm
08-C-0130A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform NeurofibromasCompleted Study; data analyses ongoing0-21 YearsNCI Benign
07-C-0100Collection of Blood from Patients with Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Neoplasm
06-C-0213Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)Participants currently recruited/enrolled0-125 YearsNCI Neoplasm
06-C-0134Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1Completed Study; data analyses ongoing20-99 YearsNCI Benign
05-CC-0091Electromagnetic Tracking of Devices During Interventional ProceduresEnrolling by Invitation18-120 YearsCC Neoplasm
04-H-0012Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family MembersParticipants currently recruited/enrolled2-100 YearsNHLBINeoplasm
04-C-0232A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of RelapseCompleted Study; data analyses ongoing18-125 YearsNCI Neoplasm
04-C-0165Data Collection, Clinical Care and Interventions in CCR, NCIEnrolling by Invitation0-120 YearsNCI Neoplasm
03-C-0066Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal CancerParticipants currently recruited/enrolled2-125 YearsNCI Benign
02-I-0286Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic SyndromeParticipants currently recruited/enrolled2-125 YearsNIAIDNeoplasm
02-C-0159Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary CystsParticipants currently recruited/enrolled2-125 YearsNCI Neoplasm
99-C-0099Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or TrichothiodystrophyNo longer recruiting/follow-up only0-125 YearsNCI Neoplasm
97-CH-0076A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related DisordersParticipants currently recruited/enrolled3-70 YearsNICHDNeoplasm
97-C-0147Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant DiseasesParticipants currently recruited/enrolled2-125 YearsNCI Neoplasm
94-HG-0132The Phenotype and Etiology of Proteus SyndromeParticipants currently recruited/enrolled0-99 YearsNHGRIBenign
93-I-0063Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T CellsParticipants currently recruited/enrolled0-99 YearsNIAIDBenign
78-C-0039Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of CancerNo longer recruiting/follow-up only0-125 YearsNCI Neoplasm